GlaxoSmithKline S.A.E (EGX:BIOC)

Egypt flag Egypt · Delayed Price · Currency is EGP
62.30
+0.04 (0.06%)
At close: Jan 28, 2026
63.26%
Market Cap5.39B +74.3%
Revenue (ttm)3.74B +33.3%
Net Income98.36M -17.7%
EPS1.17 -18.3%
Shares Out83.51M
PE Ratio55.08
Forward PEn/a
Dividend1.00 (1.55%)
Ex-Dividend DateJan 12, 2026
Volume126,332
Average Volume54,288
Open62.26
Previous Close62.26
Day's Range59.21 - 62.80
52-Week Range32.66 - 81.50
Beta1.04
RSI62.53
Earnings DateMar 5, 2026

About GlaxoSmithKline S.A.E

GlaxoSmithKline S.A.E. engages in production of pharmaceutical chemicals. The company is involved in manufacture of general and specialty medicines, and vaccines. GlaxoSmithKline S.A.E. was founded in 1981 and is based in London, the United Kingdom. GlaxoSmithKline S.A.E operates as a subsidiary of Glaxo Group Limited. [Read more]

Industry Pharmaceutical Preparations
Founded 1981
Employees 800
Stock Exchange Egyptian Stock Exchange
Ticker Symbol BIOC
Full Company Profile

Financial Performance

In 2024, GlaxoSmithKline S.A.E's revenue was 2.99 billion, an increase of 33.51% compared to the previous year's 2.24 billion. Earnings were 173.98 million, an increase of 187.78%.

Financial Statements